MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois. Show more
Location: 444 West Lake Street, Chicago, IL, 60606, United States | Website: https://maiabiotech.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
54.46M
52 Wk Range
$1.40 - $4.24
Previous Close
$1.77
Open
$1.80
Volume
94,026
Day Range
$1.75 - $1.82
Enterprise Value
42.78M
Cash
10.86M
Avg Qtr Burn
-4.08M
Insider Ownership
23.33%
Institutional Own.
4.88%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
THIO Details Non-small cell lung carcinoma, Cancer | Phase 3 Initiation | |
THIO Details Non-small cell lung carcinoma, Cancer, Hepatocellular carcinoma, Small cell lung cancer, Colorectal cancer | Phase 2 Update |